Latest Research: New Vaccines

From RSV to Group B Strep and combined COVID-influenza immunizations, these new vaccines in the pipeline represent exciting scientific advances. Although they’re not quite ready for patients’ arms, click through this slideshow and learn more about the new vaccines in the pipeline.

Disclosures: Multiple authors of each study reported industry relationships. Please see the individual abstracts for further details.

References

1. Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: Results from a phase 1, randomized clinical trial. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 234.
2. Chandler R, Montenegro N, Llorach C, et al. Immunogenicity, reactogenicity, and safety of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine coadministered with the seasonal quadrivalent influenza vaccine in older adults. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 2139.
3. Jongihlati B, Segall N, Block S, et al. A phase 2 study to evaluate the safety, tolderability, and immunogenicity of a booster dose of Group B Streptococcus 6-valent polysaccharide conjugate vaccine (GBS6). Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 2134.
4. Shinde V, Woo W, Lui S, et al. Safety and immunogenicity of COVID influenza combination vaccine. Presented at: IDWeek 2022; October 19-23, 2022; Washington, D.C. Poster 2142.